140 related articles for article (PubMed ID: 2442449)
1. Proteases and antiproteases related to the coagulation system in plasma and ascites--an approach to differentiate between malignant and cirrhotic ascites.
Schölmerich J; Zimmermann U; Köttgen E; Volk BA; Ehlers S; Gerok W
Klin Wochenschr; 1987 Jul; 65(14):634-8. PubMed ID: 2442449
[TBL] [Abstract][Full Text] [Related]
2. Proteases and antiproteases related to the coagulation system in plasma and ascites--influence of dexamethasone.
Schölmerich J; Zimmermann U; Köttgen E; Volk BA; Hasler C; Diener W; Gerok W
Klin Wochenschr; 1987 Jul; 65(14):639-42. PubMed ID: 3306136
[TBL] [Abstract][Full Text] [Related]
3. Proteases and antiproteases related to the coagulation system in plasma and ascites. Prediction of coagulation disorder in ascites retransfusion.
Schölmerich J; Zimmermann U; Köttgen E; Volk BA; Hasler C; Wilms H; Costabel U; Gerok W
J Hepatol; 1988 Jun; 6(3):359-63. PubMed ID: 2455746
[TBL] [Abstract][Full Text] [Related]
4. Proteases and antiproteases in ascites--differentiation of malignant and nonmalignant ascites and prediction of coagulopathy in ascites retransfusion.
Schölmerich J; Köttgen E; Volk BA; Gerok W
Adv Exp Med Biol; 1988; 240():555-60. PubMed ID: 3072859
[No Abstract] [Full Text] [Related]
5. Influence of plasma protease inhibitors and the secretory leucocyte protease inhibitor on leucocyte elastase-induced consumption of selected plasma proteins in vitro in man.
Björk P; Axelsson L; Bergenfeldt M; Ohlsson K
Scand J Clin Lab Invest; 1988 Apr; 48(2):205-11. PubMed ID: 2451859
[TBL] [Abstract][Full Text] [Related]
6. Proteases and protease inhibitors in cerulein-induced acute pancreatitis in rats.
Kruse P; Lasson A; Hage E
J Surg Res; 1999 Aug; 85(2):294-300. PubMed ID: 10423332
[TBL] [Abstract][Full Text] [Related]
7. Improved prognosis of fulminant hepatic failure (FHF) after plasma derivative replacement therapy. Enhanced proteolysis of hemostatic proteins confirmed by proteinase-inhibitor complexes determination.
Egbring R; Seitz R
Z Gastroenterol; 1990 Feb; 28(2):104-9. PubMed ID: 2138832
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitor and gastric cancer.
Tsumoto S; Oyabu H; Kageyama T
Bull Osaka Med Sch; 1983 Jul; 29(1):18-26. PubMed ID: 6204707
[No Abstract] [Full Text] [Related]
9. Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment according to Protocol I of the Cooperative Leukaemia Study COALL-80.
Reitz M; Witzke G; Egbring R; Gutjahr P
Klin Wochenschr; 1984 Dec; 62(24):1165-9. PubMed ID: 6085131
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
11. Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets.
Rao AK; Schmaier AH; Colman RW
Pathobiol Annu; 1982; 12():35-64. PubMed ID: 6186978
[No Abstract] [Full Text] [Related]
12. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
[TBL] [Abstract][Full Text] [Related]
14. Plasmin inhibitors in different fibrinolytic treatment patterns.
Lasierra J; Diez M; Perera C; Viladés E
Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
[TBL] [Abstract][Full Text] [Related]
15. Proteases and protease inhibitors in taurocholate-induced acute pancreatitis in rats.
Kruse P; Hage E; Lasson A
Int J Pancreatol; 1999 Apr; 25(2):113-21. PubMed ID: 10360224
[TBL] [Abstract][Full Text] [Related]
16. Components of the kallikrein-kinin-system in patients with ARDS.
Fuhrer G; Heller W; Junginger W; Gröber O; Roth K
Prog Clin Biol Res; 1989; 308():737-42. PubMed ID: 2476827
[No Abstract] [Full Text] [Related]
17. [Clinical significance of fibronectin and protease inhibitors in chronic obstructive pulmonary diseases].
Dong BR
Zhonghua Jie He He Hu Xi Za Zhi; 1989 Dec; 12(6):343-6, 381. PubMed ID: 2483984
[TBL] [Abstract][Full Text] [Related]
18. [Changes in coagulation and fibrinolysis cascades upon extracorporeal circulation].
Kanamori N; Koiwa F; Uda S
Nihon Rinsho; 1991 Dec; 49 Suppl():81-6. PubMed ID: 1839690
[No Abstract] [Full Text] [Related]
19. Fibrinolytic study in plasma and ascitic fluid of cirrhotic patients before and after ascites concentration; reinfusion technique.
Patrassi GM; Martinelli S; Sturniolo GC; Cappellato MG; Vicariotto M; Girolami A
Eur J Clin Invest; 1985 Aug; 15(4):161-5. PubMed ID: 2412833
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin concentration in ascites differentiates between malignant and nonmalignant ascites.
Schölmerich J; Volk BA; Köttgen E; Ehlers S; Gerok W
Gastroenterology; 1984 Nov; 87(5):1160-4. PubMed ID: 6479538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
